The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate hypertension.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
150
Systolic and Diastolic blood pressure
Time frame: 28 day treatment period
Glucose dynamics and insulin sensitivity
Time frame: 28 day treatment period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo taken in TID dosing regimen for 28 days
Arete Investigational site
Mobile, Alabama, United States
Arete Investigational site
Muscle Shoals, Alabama, United States
Arete Investigational site
Anaheim, California, United States
Arete Investigational site
Concord, California, United States
Arete Investigational site
Mission Hills, California, United States
Arete Investigational site
Bradenton, Florida, United States
Arete Investigational site
DeLand, Florida, United States
Arete Investigational site
Jacksonville, Florida, United States
Arete Investigational site
Largo, Florida, United States
Arete Investigational site
Miami, Florida, United States
...and 20 more locations